L&C China, a subsidiary of L&C Bio, has announced its official entry into the animal-derived tissue graft market. The company has already established a 680 square meter GMP production facility dedicated to animal tissues, in addition to its existing human tissue GMP production facilities.

L&C China plans to obtain NMPA approval for products utilizing animal-derived skin, bone, and cartilage in the Chinese market through a customized strategy based on in-depth analysis of the local transplantation market. Animal-derived tissue grafts find applications in various medical fields, including dentistry, general surgery, and plastic surgery.

The company aims to expand its product portfolio beyond its flagship human tissue grafts, MegaDerm® (skin), MegaCarti® (cartilage), and MegaBone® (bone), into the animal-derived tissue graft segment. By developing products tailored to the specific needs of patients and medical professionals, L&C China expects to enhance treatment outcomes and patient satisfaction.

In collaboration with its parent company, L&C Bio, L&C China is preparing to supply products to both the Korean and international markets. MegaCartilage-E®, a product primarily composed of horse cartilage, will be manufactured in China under an OEM arrangement and supplied to Korea. This shift in production is expected to increase production capacity by up to tenfold, enabling the company to meet both domestic and overseas demand.

L&C China has secured a monopoly supply contract for horse cartilage raw materials from local farms with the full support of the Inner Mongolia Autonomous Region government. Additionally, the company plans to supply a complex animal-derived hemostatic agent to Korea through OEM production, following approval from the Korea Food and Drug Administration.

“By entering the animal-derived tissue graft business, we aim to accelerate localization in China and embark on OEM supply,” said Kim Dong-hyun, CEO of L&C China. “We will do our utmost to ensure the early establishment of our business in China.”

[Copyright (c) Global Economic Times. All Rights Reserved.]